கிரிஸ் வெள்ளை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from கிரிஸ் வெள்ளை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In கிரிஸ் வெள்ளை Today - Breaking & Trending Today

New combination of drugs may help treat COVID-19


Written by Erika Watts on May 4, 2021 Fact checked by Ferdinand Lali, Ph.D.
A recent study tests combinations of drugs for the treatment of COVID-19. Himanshu Vyas/Hindustan Times via Getty Images
Although vaccines are now available for most of the world, a more successful treatment for COVID-19 is still necessary.
Researchers believe that a combination of Food and Drug Administration (FDA)-approved antiviral medications could help people with SARS-CoV-2 infections.
They combined the drug remdesivir, which is effective against Ebola, with drugs that can treat hepatitis C.
With worldwide COVID-19 cases on the rise again, the race to find an effective treatment for the disease continues. ....

New York , United States , Rensselaer Polytechnic Institute , United Kingdom , City Of , Adolfo Garcia Sastre , Kris White , Jonathan Stoye , Chris Coleman , Robertm Krug , Gaetano Montelione , Rensselaer Polytechnic Institute In Troy , University Of Nottingham , World Health Organization , Drug Administration , Francis Crick Institute , Hindustan Times , Mount Sinai Hospital , New York City , Cell Reports , Icahn Mount Sinai , Medical News Today , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ரென்சீலர் பாலிடெக்நிக் நிறுவனம் , ஒன்றுபட்டது கிஂக்டம் ,

University of Texas at Austin: Hepatitis C Drugs Boost Remdesivir's Antiviral Activity Against COVID-19 – India Education | Latest Education News India | Global Educational News


Share
Remdesivir is currently the only antiviral drug approved in the U.S. for treating COVID-19 patients. In a paper published this week in Cell Reports, researchers from The University of Texas at Austin, Rensselaer Polytechnic Institute (RPI) and the Icahn School of Medicine at Mount Sinai showed that four drugs used to treat hepatitis C render remdesivir 10 times better at inhibiting the coronavirus in cell cultures.
These results indicate that a mixture containing remdesivir and a repurposed hepatitis C virus (HCV) drug could potentially function as a combination antiviral therapy for SARS-CoV-2. Such an antiviral could provide an immediate treatment for unvaccinated people who become infected and for vaccinated people whose immunity has waned. ....

United States , Balasubramanian Harish , Kris White , Thomas Kehrer , Thomasb Acton , Gaetano Montelione , Adolfo Garc , Helena Moreno , Theresaa Ramelot , Catherine Royer , Khushboo Bafna , Robertm Krug , Romel Rosales , University Of Texas At Austin , Icahn School Of Medicine At Mount Sinai , Rensselaer Polytechnic Institute , Cell Reports , Icahn School , Mount Sinai , Lisa Miorin , ஒன்றுபட்டது மாநிலங்களில் , கிரிஸ் வெள்ளை , எலெனா மேலும் , கேத்தரின் ரோயர் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் இல் ஆஸ்டின் , இக்ஹ்ன் பள்ளி ஆஃப் மருந்து இல் ஏற்ற சினை ,

Medications for Hepatitis C Enhance Remdesivir's Activity


Medications for Hepatitis C Enhance Remdesivir s Activity
by Angela Mohan on 
April 28, 2021 at 6:34 PM
Cell Reports.
Mixture containing remdesivir and a repurposed hepatitis C virus (HCV) drug could potentially function as a combination antiviral therapy for SARS-CoV-2. Such an antiviral could provide an immediate treatment for unvaccinated people who become infected and for vaccinated people whose immunity has waned.
But Remdesivir must be administered intravenously, limiting its use to patients already admitted to the hospital.
Our goal is to develop a combination of oral drugs that can be administered to outpatients before they are sick enough to require hospitalization, said Robert M. Krug, professor emeritus of molecular biosciences at UT Austin and co-author of the paper. ....

Balasubramanian Harish , Kris White , Toxicityhepatitis Ahepatitis Bvasculitissilent , Khushboo Bafna , Robertm Krug , Gaetano Montelione , Adolfo Garc , Mount Sinai , Scales Up Remdesivir Production , Covid 19 , Hepatitis C , Icahn School Of Medicine , Mount Sinai , Ars Cov 2 , கிரிஸ் வெள்ளை , ஏற்ற சினை ,

Hepatitis C drugs combined with Remdesivir show strong effectiveness against covid-19


IMAGE: Synergy Scores
Mount Sinai Health System
A combination of remdesivir, a drug currently approved in the United States for treating COVID-19 patients, and repurposed drugs for hepatitis C virus (HCV) was 10 times more effective at inhibiting SARS-CoV-2, the virus that causes COVID-19.
The combination therapy points a way toward a treatment for unvaccinated people who become infected, as well as for vaccinated people whose immunity has waned, for example due to the emergence of virus variants that escape this immune protection.
Four HCV drugs simeprevir, vaniprevir, paritaprevir, and grazoprevir in combination with remdesivir boosted the efficacy of remdesivir by as much as 10-fold, the researchers reported today in ....

United States , Adolfo Garcia Sastre , Kris White , Arthurm Fishberg , Robertm Krug , Gaetano Montelione , Rensselaer Polytechnic Institute , Drug Administration , Rensselaer Center , University Of Texas At Austin , Pathogens Institute At Icahn Mount Sinai , Icahn School Of Medicine At Mount Sinai , Global Health , Icahn School , Mount Sinai , Icahn Mount Sinai , Emerging Pathogens Institute , Assistant Professor , Icahn Mount , Professor Emeritus , Molecular Biosciences , Interdisciplinary Studies , ஒன்றுபட்டது மாநிலங்களில் , கிரிஸ் வெள்ளை , ரென்சீலர் பாலிடெக்நிக் நிறுவனம் , ரென்சீலர் மையம் ,

Hepatitis C Drugs Boost Remdesivir's Antiviral Activity Against COVID-19


Hepatitis C Drugs Boost Remdesivir’s Antiviral Activity Against COVID-19
Drugs used to treat hepatitis C render remdesivir 10 times better at inhibiting the coronavirus in cell cultures, according to new study. Illustration credit: Jenna Luecke/University of Texas at Austin.
AUSTIN, Texas Remdesivir is currently the only antiviral drug approved in the U.S. for treating COVID-19 patients. In a paper published this week in
Cell Reports, researchers from The University of Texas at Austin, Rensselaer Polytechnic Institute (RPI) and the Icahn School of Medicine at Mount Sinai showed that four drugs used to treat hepatitis C render remdesivir 10 times better at inhibiting the coronavirus in cell cultures. ....

United States , Balasubramanian Harish , Kris White , Thomas Kehrer , Thomasb Acton , Gaetano Montelione , Adolfo Garc , Helena Moreno , Theresaa Ramelot , Catherine Royer , Khushboo Bafna , Robertm Krug , Romel Rosales , University Of Texas At Austin , Icahn School Of Medicine At Mount Sinai , Defense Advanced Research Projects Agency , Department Of Defense , National Institute Of Allergy , National Institutes Of Health , Rensselaer Polytechnic Institute , Cell Reports , Icahn School , Mount Sinai , Lisa Miorin , National Institutes , Computational Innovations ,